Healius (ASX:HLS) Common Stock : A$2,604 Mil (As of Dec. 2023)

View and export this data going back to 1998. Start your Free Trial

What is Healius Common Stock?

Healius's quarterly common stock increased from Dec. 2022 (A$2,421 Mil) to Jun. 2023 (A$2,421 Mil) and increased from Jun. 2023 (A$2,421 Mil) to Dec. 2023 (A$2,604 Mil).

Healius's annual common stock declined from Jun. 2021 (A$2,572 Mil) to Jun. 2022 (A$2,423 Mil) and declined from Jun. 2022 (A$2,423 Mil) to Jun. 2023 (A$2,421 Mil).

Healius Common Stock Historical Data

The historical data trend for Healius's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Healius Common Stock Chart

Healius Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Common Stock

Get a 7-Day Free Trial

2,671.10

2,672.30

2,572.00

2,422.90

2,421.00

Healius Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Common Stock	Get a 7-Day Free Trial															2,461.30	2,422.90	2,420.90	2,421.00	2,603.90

Healius Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Healius (ASX:HLS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Healius Ltd (ASX:HLS) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

161 Castlereagh Street, Level 22, Sydney, NSW, AUS, 2000

Website

https://www.healius.com.au

Healius is Australia's second-largest pathology provider and third-largest diagnostic imaging provider. Pathology and imaging revenue is almost entirely earned via the public health Medicare system. Healius typically earns approximately 75% of revenue from pathology and 25% from diagnostic imaging.

Healius (ASX:HLS) Headlines

No Headlines